Zhu M, Sali R, Baba F, Khasawneh H, Ryndin M, Leveillee R
Am J Clin Exp Urol. 2024; 12(4):200-215.
PMID: 39308594
PMC: 11411179.
DOI: 10.62347/JSAE9732.
Nam R, Benatar T, Amemiya Y, Seth A
Cancer Genomics Proteomics. 2021; 18(3):197-206.
PMID: 33893074
PMC: 8126337.
DOI: 10.21873/cgp.20252.
Meissner V, Jahnen M, Herkommer K
Urologe A. 2021; 60(5):567-575.
PMID: 33721089
DOI: 10.1007/s00120-021-01491-y.
Kim D, Jeong S, Lee J
J Cancer. 2020; 11(16):4716-4723.
PMID: 32626518
PMC: 7330688.
DOI: 10.7150/jca.45369.
Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B
Medicine (Baltimore). 2020; 99(7):e18993.
PMID: 32049793
PMC: 7035107.
DOI: 10.1097/MD.0000000000018993.
Heparan sulfate inhibits transforming growth factor β signaling and functions in cis and in trans to regulate prostate stem/progenitor cell activities.
Rai S, Alsaidan O, Yang H, Cai H, Wang L
Glycobiology. 2019; 30(6):381-395.
PMID: 31829419
PMC: 7416765.
DOI: 10.1093/glycob/cwz103.
Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer.
Bi C, Zhang G, Bai Y, Zhao B, Yang H
Medicine (Baltimore). 2019; 98(36):e16705.
PMID: 31490362
PMC: 6738968.
DOI: 10.1097/MD.0000000000016705.
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Samli H, Samli M, Vatansever B, Ardicli S, Aztopal N, Dincel D
World J Urol. 2018; 37(6):1117-1126.
PMID: 30244336
DOI: 10.1007/s00345-018-2501-6.
Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.
Tan S, Petrovics G, Srivastava S
Int J Mol Sci. 2018; 19(4).
PMID: 29690565
PMC: 5979433.
DOI: 10.3390/ijms19041255.
Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review.
Song W, Kim S, Joung J, Park W, Seo H, Chung J
J Korean Med Sci. 2017; 32(2):377-381.
PMID: 28049253
PMC: 5220008.
DOI: 10.3346/jkms.2017.32.2.377.
Mutational Landscape of Aggressive Prostate Tumors in African American Men.
Lindquist K, Paris P, Hoffmann T, Cardin N, Kazma R, Mefford J
Cancer Res. 2016; 76(7):1860-8.
PMID: 26921337
PMC: 4772140.
DOI: 10.1158/0008-5472.CAN-15-1787.
Identification of candidate genes for prostate cancer-risk SNPs utilizing a normal prostate tissue eQTL data set.
Thibodeau S, French A, McDonnell S, Cheville J, Middha S, Tillmans L
Nat Commun. 2015; 6:8653.
PMID: 26611117
PMC: 4663677.
DOI: 10.1038/ncomms9653.
Genome-wide detection of allelic genetic variation to predict biochemical recurrence after radical prostatectomy among prostate cancer patients using an exome SNP chip.
Oh J, Park S, Lee S, Hong S, Lee S, Lee H
J Cancer Res Clin Oncol. 2015; 141(8):1493-501.
PMID: 25764380
DOI: 10.1007/s00432-015-1947-9.
A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients.
Oh J, Park S, Lee S, Hong S, Lee S, Lee H
Korean J Urol. 2015; 56(2):109-16.
PMID: 25685297
PMC: 4325114.
DOI: 10.4111/kju.2015.56.2.109.
Analysis of candidate genes has proposed the role of y chromosome in human prostate cancer.
Khosravi P, Zahiri J, Gazestani V, Mirkhalaf S, Akbarzadeh M, Sadeghi M
Iran J Cancer Prev. 2015; 7(4):204-11.
PMID: 25628841
PMC: 4307103.
Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer.
Cremers R, Galesloot T, Aben K, van Oort I, Vasen H, Vermeulen S
Prostate. 2015; 75(5):474-83.
PMID: 25560306
PMC: 6680338.
DOI: 10.1002/pros.22933.
KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.
Zazzeroni F, Nicosia D, Tessitore A, Gallo R, Verzella D, Fischietti M
Biomed Res Int. 2014; 2014:380398.
PMID: 25045667
PMC: 4090506.
DOI: 10.1155/2014/380398.
"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer.
Bancroft E, Castro E, Ardern-Jones A, Moynihan C, Page E, Taylor N
Fam Cancer. 2014; 13(4):625-35.
PMID: 24980079
DOI: 10.1007/s10689-014-9734-3.
An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk.
Xie Y, You C, Chen J
Tumour Biol. 2014; 35(7):6567-79.
PMID: 24691970
DOI: 10.1007/s13277-014-1842-z.
Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis.
Ma L, Zhao J, Li T, He Y, Wang J, Xie L
Diagn Pathol. 2014; 9:74.
PMID: 24666463
PMC: 3977697.
DOI: 10.1186/1746-1596-9-74.